A 2023 meta-analysis encompassing 29 trials found that among advanced EGFR-mutant NSCLC patients treated with EGFR TKIs, those whose tumors harbored concurrent TP53 mutations had significantly shorter progression-free survival (PFS) and overall survival (OS) compared to those with only the EGFR driver [41]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.